These findings suggest that HMOs, like 2’-FL, may reduce β-lactoglobulin allergy by modulating miR-146a to inhibit the TLR4/NFκB signaling pathway (80) hindering the subsequent inflammatory response. This evidence concerns the gene NFKB1 and allergic disease.